ArticlePloS one2014
KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Chemical and Technological Aspects of Magnetic Particles for Cancer Liquid Biopsy Applications.ChemistryOpen · 2026Review
- Correlation betweenGenes · 2023Article
- Extracellular Vesicles' Genetic Cargo as Noninvasive Biomarkers in Cancer: A Pilot Study Using ExoGAG Technology.Biomedicines · 2023Article
- Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer.Journal of experimental & clinical cancer research : CR · 2022Review
- Circulating tumor cells: biology and clinical significance.Signal transduction and targeted therapy · 2021Review
- Detection and clinical significance of circulating tumor cells in colorectal cancer.Biomarker research · 2021Review
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer.Cancers · 2021Review
- Mesenchymal Characteristics and Predictive Biomarkers on Circulating Tumor Cells for Therapeutic Strategy.Cancers · 2020Review
- Genomic Instability in Circulating Tumor Cells.Cancers · 2020Review
- Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples.Journal of experimental & clinical cancer research : CR · 2020Review
- KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients.International journal of colorectal disease · 2020Article
- Perspectives of the Application of Liquid Biopsy in Colorectal Cancer.BioMed research international · 2020Review
- Panitumumab-IRDye800CW for Fluorescence-Guided Surgical Resection of Colorectal Cancer.The Journal of surgical research · 2019Article
- Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse.Ecancermedicalscience · 2019Article
- Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients.Oncotarget · 2017Article
- Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer.Translational oncology · 2017Article
- Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?American journal of translational research · 2017Article
- Deregulation of the miR-16-KRAS axis promotes colorectal cancer.Scientific reports · 2016Article
- The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care.Therapeutic advances in gastroenterology · 2016Review
- Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCirculating tumor cells (CTCs) could represent a non-invasive source of cancer cells used for longitudinal monitoring of the tumoral mutation status throughout the course of the disease. The aims of the present study were to investigate the detection of KRAS mutations in CTCs from patients with metastatic colorectal cancer (mCRC) and to compare their mutation status during treatment or disease progression with that of the corresponding primary tumors. MATERIALS AND
methodsIdentification of the seven most common KRAS mutations on codons 12 and 13 was performed by Peptide Nucleic Acid (PNA)-based qPCR method. The sensitivity of the assay was determined after isolation of KRAS mutant cancer cells spiked into healthy donors' blood, using the CellSearch Epithelial Cell kit. Consistent detection of KRAS mutations was achieved in samples containing at least 10 tumor cells/7.5 ml of blood.
resultsThe clinical utility of the assay was assessed in 48 blood samples drawn from 31 patients with mCRC. All patients had PIK3CA and BRAF wild type primary tumors and 14 KRAS mutant tumors. CTCs were detected in 65% of specimens obtained from 74% of patients. KRAS mutation analysis in CTC-enriched specimens showed that 45% and 16.7% of patients with mutant and wild type primary tumors, respectively, had detectable mutations in their CTCs. Assessing KRAS mutations in serial blood samples revealed that individual patient's CTCs exhibited different mutational status of KRAS during treatment.
conclusionsThe current findings support the rationale for using the CTCs as a dynamic source of tumor cells which, by re-evaluating their KRAS mutation status, could predict, perhaps more accurately, the response of mCRC patients to targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.